Skip to main content

CORRECTION article

Front. Pharmacol., 12 June 2023
Sec. Respiratory Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1228923

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

This article is a correction to:

  1. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    1. Read original article
Daniel Morales-Cano,,,,&#x;Daniel Morales-Cano1,2,3,4,5†Jose Luis Izquierdo-García,,&#x;Jose Luis Izquierdo-García2,6,7†Bianca Barreira,,Bianca Barreira1,2,3Sergio Esquivel-Ruiz,,Sergio Esquivel-Ruiz1,2,3Maria Callejo,,Maria Callejo1,2,3Rachele Pandolfi,,Rachele Pandolfi1,2,3Palmira Villa-Valverde,Palmira Villa-Valverde2,8Ignacio Rodríguez,Ignacio Rodríguez2,6Angel Cogolludo,,Angel Cogolludo1,2,3Jesus Ruiz-Cabello,,Jesus Ruiz-Cabello2,6,9Francisco Perez-Vizcaino,,&#x;Francisco Perez-Vizcaino1,2,3‡Laura Moreno,, &#x;Laura Moreno1,2,3*‡
  • 1Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
  • 2Ciber Enfermedades Respiratorias (Ciberes), Madrid, Spain
  • 3Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
  • 4Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
  • 5Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
  • 6Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain
  • 7Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, Spain
  • 8ICTS Bioimagen Complutense, Universidad Complutense de Madrid, Madrid, Spain
  • 9Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia San Sebastián, Spain

A Corrigendum on
Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

by Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023). Front. Pharmacol. 14:1021535. doi: 10.3389/fphar.2023.1021535

In the published article, there was an error in Figure 2 as published. There was a mistake in the identification of two of the panels (B and C) which were described respectively as “(B) systolic PAP (sPAP) and (C) diastolic PAP (dPAP).” The corrected Figure 2, and it is caption, appear below.

FIGURE 2
www.frontiersin.org

FIGURE 2. Treatment with riociguat alone or combined with 5-z-7oxozeaenol attenuates pulmonary hypertension in the Sugen 5426/hypoxia (SuHyp) rat model. (A) Mean pulmonary arterial pressure (mPAP), (B) diastolic PAP (dPAP) and (C) systolic PAP (sPAP) in control (NMX-Vh) and SuHyp rats treated with vehicle, 5Z-7-oxozeaenol (SuHyp-OXO; 3 mg·kg−1·day−1), riociguat (SuHyp-RIO; 3 mg·kg−1·day−1) or both drugs combined (SuHyp-OXO-RIO). (D) Representative PAP recordings in each treatment group. (E) Right systolic and (F) end-diastolic ventricular pressure (RVSP and RVEDP). (G) Fulton index (ratio between RV and left ventricle plus septum weight) and (H) right ventricular weight relative to total body weight in the different treatment groups. Each bar shows the mean +SEM (n = 6–10 animals in each group). *p < 0.05 versus NMX-Vh and #p < 0,05 versus SuHyp vehicle (One-way ANOVA followed by Bonferroni´s post hoc test).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pulmonary hypertension, antiproliferative, metabolomics, combination therapy, right ventricle

Citation: Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023) Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. Front. Pharmacol. 14:1228923. doi: 10.3389/fphar.2023.1228923

Received: 25 May 2023; Accepted: 30 May 2023;
Published: 12 June 2023.

Edited and reviewed by:

Alessia Vignoli, University of Florence, Italy

Copyright © 2023 Morales-Cano, Izquierdo-García, Barreira, Esquivel-Ruiz, Callejo, Pandolfi, Villa-Valverde, Rodríguez, Cogolludo, Ruiz-Cabello, Perez-Vizcaino and Moreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Laura Moreno, lmorenog@med.ucm.es

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.